{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:50:53Z","timestamp":1790985053271,"version":"4.1.0"},"reference-count":223,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Testicular germ cell tumors (TGCTs) are the most common solid malignancies in young men and, despite high cure rates with cisplatin-based multimodal therapy, a clinically relevant subset of patients develops relapsed, platinum-refractory, or treatment-resistant disease with limited salvage options and substantial long-term morbidity. This unmet need has renewed interest in immunotherapy, yet the experience in TGCT has been notably less successful than in other malignancies. Although TGCTs often display PD-L1 expression, tumor-infiltrating lymphocytes, and other features suggestive of immune engagement, immune checkpoint inhibitors have produced largely disappointing results in unselected patients, underscoring the complexity of immune regulation in this immune-privileged disease. Recent conceptual advances place microRNAs (miRNAs) at the center of this problem. Beyond their established diagnostic and prognostic value, miRNAs are increasingly recognized as upstream regulators of immune checkpoints, antigen-presentation pathways, cytokine signaling, macrophage polarization, dendritic-cell and T-cell function, and extracellular-vesicle-mediated tumor\u2013immune crosstalk. This positions miRNAs not only as biomarkers of disease activity, but also as plausible determinants of immunotherapy sensitivity or resistance. At the same time, the field remains marked by important controversies: PD-L1 expression alone is an unreliable predictor of response; the relative contribution of low tumor mutational burden, testicular immune privilege, and microenvironmental suppression remains unresolved; and many proposed TGCT-associated miRNAs with an immunoregulatory role are still inferential rather than causally validated in disease-specific models. Accordingly, major gaps persist in defining which miRNAs are true functional drivers of immune escape in seminomatous versus non-seminomatous TGCT, how they interact with therapy-induced tumor evolution, and which delivery platforms can achieve safe, tumor-directed modulation. We argue that the next phase of the field should move beyond descriptive biomarker studies toward mechanism-based, TGCT-specific translational strategies integrating miRNA mimics, antagomirs, extracellular vesicles, or miRNA-augmented cellular therapies with immune-priming approaches such as epigenetic therapy, radiotherapy, vaccines, or CAR-T platforms. Such a framework could enable more precise biological stratification and improve the efficacy, durability, and tolerability of immunotherapy in refractory TGCT.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1847225","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:48:04Z","timestamp":1781156884000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["MicroRNAs and immunotherapy in testicular germ cell tumors: opportunities and challenges for modulation of the immune microenvironment"],"prefix":"10.3389","volume":"17","author":[{"given":"Alejandro","family":"Lopez-Saavedra","sequence":"first","affiliation":[{"name":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud","place":["Ciudad de M\u00e9xico, Mexico"]},{"name":"Advanced Microscopy Applications Unit (ADMiRA)-Instituto Nacional de Cancerolog\u00eda","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"D\u00edaz-Ch\u00e1vez","sequence":"additional","affiliation":[{"name":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud","place":["Ciudad de M\u00e9xico, Mexico"]},{"name":"Instituto Nacional de Cancerolog\u00eda","place":["Ciudad de M\u00e9xico, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Jimenez-R\u00edos","sequence":"additional","affiliation":[{"name":"Department of Urology, Instituto Nacional de Cancerolog\u00eda","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Scavuzzo","sequence":"additional","affiliation":[{"name":"Department of Urology, Instituto Nacional de Cancerolog\u00eda","place":["Mexico City, Mexico"]},{"name":"Universidad Autonoma de Mexico, Faculty of Medicine, Estudios de Posgrado, Universidad Autonoma de Mexico, Universidad Nacional Autonoma de Mexico (UNAM)","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/jama.2024.27122","article-title":"Testicular germ cell tumors","volume":"333","author":"Singla","year":"2025","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.002","article-title":"Testicular seminoma and non-seminoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up \u2606","volume":"33","author":"Oldenburg","year":"2022","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11912-021-01093-z","article-title":"Current management of refractory germ cell tumors","volume":"23","author":"Abughanimeh","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2025.103169","article-title":"Advances in cell therapy for testicular cancer: a comprehensive overview of immunotherapy and stem cell therapy","volume":"98","author":"Mehr","year":"2025","journal-title":"Tissue Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/biom10071061","article-title":"Epigenetic mechanisms of resistance to immune checkpoint inhibitors","volume":"10","author":"Perrier","year":"2020","journal-title":"Biomolecules"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092250","article-title":"Epitranscriptomic approach: To improve the efficacy of ICB therapy by co-targeting intracellular checkpoint CISH","volume":"10","author":"Kumar","year":"2021","journal-title":"Cells"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031737","article-title":"miRNAs related to immune checkpoint inhibitor response: A systematic review","volume":"25","author":"Garc\u00eda-Gim\u00e9nez","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/andr.12656","article-title":"Immune mechanisms and possible immune therapy in testicular germ cell tumors","volume":"7","author":"Chovanec","year":"2019","journal-title":"Andrology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.573977","article-title":"Immunotherapy in testicular germ cell tumors","volume":"10","author":"Kalavska","year":"2020","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/onco.13682","article-title":"Pembrolizumab in patients with advanced metastatic germ cell tumors","volume":"26","author":"Tsimberidou","year":"2021","journal-title":"Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1118610","article-title":"Immune checkpoint inhibitors and chimeric antigen receptor (CAR)-T cell therapy: Potential treatment options against testicular germ cell tumors","volume":"14","author":"Schepisi","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-021-00521-x","article-title":"The diagnostic accuracy of miR-371a-3p for testicular germ cell tumors: A systematic review and meta-analysis","volume":"25","author":"Liu","year":"2021","journal-title":"Mol Diagn Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/andr.13337","article-title":"miRNAs for testicular germ cell tumors: Contemporary indications for diagnosis, surveillance and follow\u2010up","volume":"11","author":"Chavarriaga","year":"2023","journal-title":"Andrology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.06.006","article-title":"Circulating microRNAs, the next-generation serum biomarkers in testicular germ cell tumors: A systematic review","volume":"80","author":"Le\u00e3o","year":"2021","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2022.04.008","article-title":"Circulating microRNAs for detection of germ cell tumors: A narrative review","volume":"8","author":"Fankhauser","year":"2022","journal-title":"Eur Urol Focus"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132172","article-title":"MicroRNAs in cancer immunology: Master regulators of the tumor microenvironment and immune evasion, with therapeutic potential","volume":"17","author":"Zare","year":"2025","journal-title":"Cancers"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009774","article-title":"Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy","volume":"12","author":"Vaxevanis","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15000","article-title":"Immunomodulatory microRNAs in cancer: targeting immune checkpoints and the tumor microenvironment","volume":"286","author":"Omar","year":"2019","journal-title":"FEBS J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/s0140-6736(25)00455-6","article-title":"Testicular cancer","volume":"406","author":"Chavarriaga","year":"2025","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/edbk-25-472654","article-title":"Key updates in testicular cancer: Optimizing survivorship and survival","volume":"45","author":"Bagrodia","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.eururo.2023.04.010","article-title":"European Association of Urology guidelines on testicular cancer: 2023 update","volume":"84","author":"Patrikidou","year":"2023","journal-title":"Eur Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/cco.0000000000000446","article-title":"Managing seminomatous and nonseminomatous germ cell tumors","volume":"30","author":"Chahoud","year":"2018","journal-title":"Curr Opin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0237-2","article-title":"Vaccination with inhibin-\u03b1 provides effective immunotherapy against testicular stromal cell tumors","volume":"5","author":"Aguilar","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/cco.0000000000001129","article-title":"Novel therapeutics in refractory germ cell tumors","volume":"37","author":"Richardson","year":"2025","journal-title":"Curr Opin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1425","article-title":"Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets","volume":"13","author":"Alahdal","year":"2023","journal-title":"Clin Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071587","article-title":"miRNAs and lncRNAs as novel therapeutic targets to improve cancer immunotherapy","volume":"13","author":"Di","year":"2021","journal-title":"Cancers"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082805","article-title":"microRNAs in the antitumor immune response and in bone metastasis of breast cancer: From biological mechanisms to therapeutics","volume":"21","author":"Gomarasca","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/biom12070930","article-title":"MicroRNAs at the crossroad between immunoediting and oncogenic drivers in hepatocellular carcinoma","volume":"12","author":"Gramantieri","year":"2022","journal-title":"Biomolecules"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab006","article-title":"MicroRNAs: immune modulators in cancer immunotherapy","volume":"1","author":"Xing","year":"2021","journal-title":"Immunother Adv"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115104","article-title":"Recent progress in the immunotherapy of hepatocellular carcinoma: Non-coding RNA-based immunotherapy may improve the outcome","volume":"165","author":"Afra","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/biology12060877","article-title":"Chasing the role of miRNAs in RCC: From free-circulating to extracellular-vesicle-derived biomarkers","volume":"12","author":"Mastrolia","year":"2023","journal-title":"Biology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147743","article-title":"Advancements in personalized CAR-T therapy: Comprehensive overview of biomarkers and therapeutic targets in hematological Malignancies","volume":"25","author":"Olejarz","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.06.020","article-title":"Chimeric antigen receptor therapy: How are we driving in solid tumors","volume":"26","author":"Greenbaum","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35369","article-title":"Cancer metastases: Tailoring the targets","volume":"10","author":"Pote","year":"2024","journal-title":"Heliyon"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310859","article-title":"Current understanding on why ovarian cancer is resistant to immune checkpoint inhibitors","volume":"24","author":"Paw\u0142owska","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03109","article-title":"Therapeutic cancer vaccines-T cell responses and epigenetic modulation","volume":"9","author":"AER","year":"2019","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101694","article-title":"RNA-based therapeutics: Current developments in targeted molecular therapy of triple-negative breast cancer","volume":"13","author":"Haque","year":"2021","journal-title":"Pharmaceutics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41419-024-06698-3","article-title":"The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications","volume":"15","author":"Ma","year":"2024","journal-title":"Cell Death Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031469","article-title":"Trials and tribulations of microRNA therapeutics","volume":"25","author":"Seyhan","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040856","article-title":"Pathogenetic features and current management of glioblastoma","volume":"13","author":"Nguyen","year":"2021","journal-title":"Cancers"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i24.3568","article-title":"Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy","volume":"27","author":"Galanopoulos","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21030878","article-title":"The miRNAs role in melanoma and in its resistance to therapy","volume":"21","author":"Varrone","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155284","article-title":"Exploring the detailed role of interleukins in cancer: A comprehensive review of literature","volume":"257","author":"Saleh","year":"2024","journal-title":"Pathol - Res Pr"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv615","article-title":"Regulation of PD-L1: a novel role of pro-survival signalling in cancer","volume":"27","author":"Chen","year":"2016","journal-title":"Ann Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2174\/1570159x19666210113152108","article-title":"Targeting glioblastoma: The current state of different therapeutic approaches","volume":"19","author":"Khan","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-025-02298-7","article-title":"Circulating microRNAs: functional biomarkers for melanoma prognosis and treatment","volume":"24","author":"Lim","year":"2025","journal-title":"Mol Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cells9081896","article-title":"Advances in therapeutic targeting of cancer stem cells within the tumor microenvironment: An updated review","volume":"9","author":"Dzobo","year":"2020","journal-title":"Cells"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244148","article-title":"Immune checkpoint inhibitors in glioblastoma IDHwt treatment: A systematic review","volume":"16","author":"Baskaran","year":"2024","journal-title":"Cancers"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315384","article-title":"Programmed cell death-ligand 1 in head and neck squamous cell carcinoma: Molecular insights, preclinical and clinical data, and therapies","volume":"23","author":"Meliante","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/biom15020269","article-title":"Mechanisms of resistance to anti-PD-1 immunotherapy in melanoma and strategies to overcome it","volume":"15","author":"Zieli\u0144ska","year":"2025","journal-title":"Biomolecules"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1539047","article-title":"Exosome, an important transmitter in the drug resistance of non-small cell lung cancer","volume":"15","author":"Ji","year":"2025","journal-title":"Front Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00048","article-title":"Long non-coding RNAs: Emerging roles in the immunosuppressive tumor microenvironment","volume":"10","author":"Luo","year":"2020","journal-title":"Front Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109979","article-title":"Hallmarks of cancer resistance","volume":"27","author":"Tufail","year":"2024","journal-title":"iScience"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071645","article-title":"Immuno-surgical management of pancreatic cancer with analysis of cancer exosomes","volume":"9","author":"Takeda","year":"2020","journal-title":"Cells"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581635","article-title":"Role of extracellular vesicles in cancer: Implications in immunotherapeutic resistance","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030824","article-title":"MicroRNAs with multiple targets of immune checkpoints, as a potential sensitizer for immune checkpoint inhibitors in breast cancer treatment","volume":"15","author":"Zhou","year":"2023","journal-title":"Cancers"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1177\/11782234251355663","article-title":"Recent insights into breast cancer: Molecular pathways, epigenetic regulation, and emerging targeted therapies","volume":"19","author":"Maqsood","year":"2025","journal-title":"Breast Cancer: Basic Clin Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-22-2155","article-title":"RNA therapeutics for improving CAR T-cell safety and efficacy","volume":"83","author":"Schaible","year":"2023","journal-title":"Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2442067","article-title":"Stemness regulation in prostate cancer: Prostate cancer stem cells and targeted therapy","volume":"57","author":"Liang","year":"2025","journal-title":"Ann Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1418005","article-title":"The role of ncRNAs and exosomes in the development and progression of endometrial cancer","volume":"14","author":"Niebora","year":"2024","journal-title":"Front Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.856974","article-title":"Breast cancer stem-like cells in drug resistance: A review of mechanisms and novel therapeutic strategies to overcome drug resistance","volume":"12","author":"Saha","year":"2022","journal-title":"Front Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.768009","article-title":"Biliary tract cancers: Treatment updates and future directions in the era of precision medicine and immuno-oncology","volume":"11","author":"Manne","year":"2021","journal-title":"Front Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: A Hoosier Cancer Research Network Study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113042","article-title":"Clinical outcome and prognostic factors for immunotherapy-based treatments in patients with platinum-refractory germ cell tumor","volume":"142","author":"Huang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0571","article-title":"Immunotherapy: Last bullet in platinum refractory germ cell testicular cancer","volume":"15","author":"Semaan","year":"2019","journal-title":"Futur Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020428","article-title":"The immune landscape and immunotherapeutic strategies in platinum-refractory testicular germ cell tumors","volume":"16","author":"Evmorfopoulos","year":"2024","journal-title":"Cancers"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.244","article-title":"Frequent PD-L1 expression in testicular germ cell tumors","volume":"113","author":"Fankhauser","year":"2015","journal-title":"Br J Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.02.014","article-title":"Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors","volume":"39","author":"Al-Hogbani","year":"2021","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154540","article-title":"TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis","volume":"247","author":"Melotti","year":"2023","journal-title":"Pathol - Res Pr"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2023.104184","article-title":"Frequent expression of CD45RO memory T cell marker as well as low to high expression of PD-1 and PD-L1 inhibitory molecules in seminoma and dysgerminoma","volume":"161","author":"Farahani","year":"2024","journal-title":"J Reprod Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101535","article-title":"Detailed characterization of immune cell infiltrate and expression of immune checkpoint molecules PD-L1\/CTLA-4 and MMR proteins in testicular germ cell tumors disclose novel disease biomarkers","volume":"11","author":"Lobo","year":"2019","journal-title":"Cancers"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew211","article-title":"Specific immune cell and cytokine characteristics of human testicular germ cell neoplasia","volume":"31","author":"Klein","year":"2016","journal-title":"Hum Reprod"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/andr.70181","article-title":"Recent advances in understanding the biological role of microRNA\u2010371a\u20103p in testicular germ cell tumors","author":"Klemke","year":"2026","journal-title":"Andrology"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02669-9","article-title":"T cells in testicular germ cell tumors: New evidence of fundamental contributions by rare subsets","volume":"130","author":"Islam","year":"2024","journal-title":"Br J Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1600-065x.2006.00438.x","article-title":"The testis in immune privilege","volume":"213","author":"Fijak","year":"2006","journal-title":"Immunol Rev"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-869-0_29","article-title":"Suppression and regulation of immune responses, methods and protocols","volume":"677","author":"Fijak","year":"2010","journal-title":"Methods Mol Biol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0054","article-title":"The immunotherapy revolution in genitourinary Malignancies","volume":"12","author":"U","year":"2020","journal-title":"Immunotherapy"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/mou.0000000000000531","article-title":"Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer","volume":"28","author":"Oing","year":"2018","journal-title":"Curr Opin Urol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101502","article-title":"Treatment of recurrent ovarian germ cell tumors: Is there a role for immune checkpoint inhibitors","volume":"56","author":"Bernard","year":"2024","journal-title":"Gynecol Oncol Rep"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/andr.12616","article-title":"New insights into germ cell tumor genomics","volume":"7","author":"Lafin","year":"2019","journal-title":"Andrology"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1506278","article-title":"The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers","volume":"16","author":"Kalemoglu","year":"2025","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1089\/jayao.2024.0056","article-title":"Immune checkpoint inhibitors in patients with testicular cancer: A systematic review","volume":"14","author":"Salazar-Mej\u00eda","year":"2025","journal-title":"J Adolesc Young Adult Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14885","article-title":"Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors","volume":"29","author":"Kawahara","year":"2022","journal-title":"Int J Urol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2217\/imt-2021-0259","article-title":"Long-term response to camrelizumab in a pretreated metastatic mixed testicular germ-cell tumor patient with co-mutations in DNA damage-repair genes","volume":"15","author":"Zhang","year":"2023","journal-title":"Immunotherapy"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10050972","article-title":"Overcoming chemotherapy resistance in germ cell tumors","volume":"10","author":"Orsz\u00e1ghov\u00e1","year":"2022","journal-title":"Biomedicines"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.12659\/ajcr.936552","article-title":"Metachronous testicular metastases from Merkel cell carcinoma (MCC): A case report and literature review","volume":"23","author":"Laffi","year":"2022","journal-title":"Am J Case Rep"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumors","volume":"122","author":"Hong","year":"2020","journal-title":"Br J Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Investig N Drugs"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/cells11061008","article-title":"MicroRNA as a potential therapeutic molecule in cancer","volume":"11","author":"Szczepanek","year":"2022","journal-title":"Cells"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154612","article-title":"miRNAs orchestration of testicular germ cell tumors - Particular emphasis on diagnosis, progression and drug resistance","volume":"248","author":"Elesawy","year":"2023","journal-title":"Pathol - Res Pr"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.02.037","article-title":"A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors","volume":"124","author":"Voorhoeve","year":"2006","journal-title":"Cell"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.461","article-title":"\u03b2-catenin\/LEF1 transactivates the microRNA-371\u2013373 cluster that modulates the Wnt\/\u03b2-catenin-signaling pathway","volume":"31","author":"Zhou","year":"2012","journal-title":"Oncogene"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.02.037","article-title":"Serum levels of microRNAs miR-371-3: A novel class of serum biomarkers for testicular germ cell tumors","volume":"61","author":"Belge","year":"2012","journal-title":"Eur Urol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030749","article-title":"Non-coding microRNAs as novel potential tumor markers in testicular cancer","volume":"12","author":"Regouc","year":"2020","journal-title":"Cancers"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.2741\/4749","article-title":"Recent advances in the regulation of testicular germ cell tumors by microRNAs","volume":"24","author":"Batool","year":"2019","journal-title":"Front Biosci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121637","article-title":"Identification and validation model for informative liquid biopsy-based microRNA biomarkers: insights from germ cell tumor In Vitro, In Vivo and patient-derived data","volume":"8","author":"Lobo","year":"2019","journal-title":"Cells"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10867","article-title":"Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test)","volume":"8","author":"Agthoven","year":"2016","journal-title":"Oncotarget"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.07.010","article-title":"Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer","volume":"193","author":"Syring","year":"2015","journal-title":"J Urol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.07.029","article-title":"Serum levels of microRNA miR-371a-3p: a sensitive and specific new biomarker for germ cell tumors","volume":"71","author":"Dieckmann","year":"2017","journal-title":"Eur Urol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2490-7","article-title":"Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p","volume":"143","author":"Radtke","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59112033","article-title":"The role of miRNA in testicular cancer: current insights and future perspectives","volume":"59","author":"Ditonno","year":"2023","journal-title":"Medicina"},{"key":"B102","doi-asserted-by":"publisher","first-page":"JCO.18.01480","DOI":"10.1200\/jco.18.01480","article-title":"Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study","volume":"37","author":"Dieckmann","year":"2019","journal-title":"J Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19103130","article-title":"MiR-371a-3p serum levels are increased in recurrence of testicular germ cell tumor patients","volume":"19","author":"Terbuch","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14013","article-title":"Clinical utility of plasma miR\u2010371a\u20103p in germ cell tumors","volume":"23","author":"Mego","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B105","article-title":"MicroRNAs in testicular cancer: implications for pathogenesis, diagnosis, prognosis and therapy","volume":"34","author":"Bezan","year":"2014","journal-title":"Anticancer Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02057","article-title":"Developing a highly specific biomarker for germ cell Malignancies: plasma miR371 expression across the germ cell Malignancy spectrum","volume":"37","author":"Nappi","year":"2019","journal-title":"J Clin Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000001337","article-title":"Real-world application of pre-orchiectomy miR-371a-3p test in testicular germ cell tumor management","volume":"205","author":"Badia","year":"2021","journal-title":"J Urol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.10.005","article-title":"Serum microRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-na\u00efve patients undergoing retroperitoneal lymph node dissection","volume":"77","author":"Lafin","year":"2020","journal-title":"Eur Urol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"20170338","DOI":"10.1098\/rstb.2017.0338","article-title":"Germ cell tumor subtypes display differential expression of microRNA371a-3p","volume":"373","author":"Vilela-Salgueiro","year":"2018","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1159\/000510760","article-title":"High expression of microRNA-371a-3p in cystic fluid of post-chemotherapy teratoma with concurrent normal serum levels in patients with non-seminomatous testicular germ cell tumors","volume":"105","author":"Dieckmann","year":"2021","journal-title":"Urol Int"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.10.024","article-title":"Integrated expression of circulating miR375 and miR371 to identify teratoma and active germ cell Malignancy components in Malignant germ cell tumors","volume":"79","author":"Nappi","year":"2021","journal-title":"Eur Urol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061601","article-title":"Cisplatin resistance in testicular germ cell tumors: current challenges from various perspectives","volume":"12","author":"Lobo","year":"2020","journal-title":"Cancers"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70314","article-title":"The new tumor biomarker miRNA\u2010371\u20103p influences cisplatin sensitivity of testicular germ cell tumor cell lines","volume":"28","author":"Weiten","year":"2024","journal-title":"J Cell Mol Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.187","article-title":"The cancer\/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas","volume":"115","author":"Nettersheim","year":"2016","journal-title":"Br J Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2014.12.003","article-title":"Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia","volume":"27","author":"Wang","year":"2015","journal-title":"Cell Signal"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041507","article-title":"Micro RNA molecules as modulators of treatment resistance, immune checkpoints controllers and sensitive biomarkers in glioblastoma multiforme","volume":"21","author":"Mazurek","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3390\/cells13161343","article-title":"MiRNAs as regulators of immune cells in the tumor microenvironment of ovarian cancer","volume":"13","author":"Wilczy\u0144ski","year":"2024","journal-title":"Cells"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1052731","article-title":"Exosomal microRNAs in cancer: potential biomarkers and immunotherapeutic targets for immune checkpoint molecules","volume":"14","author":"Alotaibi","year":"2023","journal-title":"Front Genet"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9030318","article-title":"MicroRNAs as predictive biomarkers of resistance to targeted therapies in gastrointestinal tumors","volume":"9","author":"Angerilli","year":"2021","journal-title":"Biomedicines"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314775","article-title":"The roles of miRNAs (microRNAs) in melanoma immunotherapy","volume":"23","author":"Dong","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213822","article-title":"miRNAs in regulation of tumor microenvironment, chemotherapy resistance, immunotherapy modulation and miRNA therapeutics in cancer","volume":"23","author":"Kousar","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2014.01.006","article-title":"MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer","volume":"75","author":"Zhu","year":"2014","journal-title":"Hum Immunol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","article-title":"Stromal cells in the tumor microenvironment: accomplices of tumor progression","volume":"14","author":"Zhao","year":"2023","journal-title":"Cell Death Dis"},{"key":"B124","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2016.12.001","article-title":"Suppression of T cells by myeloid-derived suppressor cells in cancer","volume":"78","author":"Chen","year":"2017","journal-title":"Hum Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1172\/jci98060","article-title":"Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma","volume":"128","author":"Huber","year":"2018","journal-title":"J Clin Investig"},{"key":"B129","doi-asserted-by":"publisher","first-page":"289","DOI":"10.20892\/j.issn.2095-3941.2021.0294","article-title":"Modulating microRNAs in cancer: next-generation therapies","volume":"19","author":"Arghiani","year":"2021","journal-title":"Cancer Biol Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.14800\/ccm.637","article-title":"Regulating tumor myeloid-derived suppressor cells by microRNAs","volume":"2","author":"Chen","year":"2015","journal-title":"Cancer Cell Microenviron"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m117.808121","article-title":"Antitumor immunity is defective in T cell\u2013specific microRNA-155\u2013deficient mice and is rescued by immune checkpoint blockade","volume":"292","author":"Huffaker","year":"2017","journal-title":"J Biol Chem"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2014.121","article-title":"Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth","volume":"24","author":"Yin","year":"2014","journal-title":"Cell Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656364","article-title":"Aspects of the tumor microenvironment involved in immune resistance and drug resistance","volume":"12","author":"Khalaf","year":"2021","journal-title":"Front Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3390\/biom11111648","article-title":"miRNA as a modulator of immunotherapy and immune response in melanoma","volume":"11","author":"Nguyen","year":"2021","journal-title":"Biomolecules"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2019.07.002","article-title":"Improved anti-tumor efficacy of paclitaxel in combination with microRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer","volume":"461","author":"Parayath","year":"2019","journal-title":"Cancer Lett"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020464","article-title":"Melanoma-derived exosomal miR-125b-5p educates tumor associated macrophages (TAMs) by targeting lysosomal acid lipase A (LIPA)","volume":"12","author":"Gerloff","year":"2020","journal-title":"Cancers"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.572689","article-title":"Exosomal miRNA-16-5p derived from M1 macrophages enhances T cell-dependent immune response by regulating PD-L1 in gastric cancer","volume":"8","author":"Li","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12943-019-0988-0","article-title":"MCT-1\/miR-34a\/IL-6\/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer","volume":"18","author":"Weng","year":"2019","journal-title":"Mol Cancer"},{"key":"B139","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.1038\/s41598-018-24531-8","article-title":"Regulatory T cell-derived extracellular vesicles modify dendritic cell function","volume":"8","author":"Tung","year":"2018","journal-title":"Sci Rep"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2014.09.004","article-title":"Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203","volume":"292","author":"Zhou","year":"2014","journal-title":"Cell Immunol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2015.1062968","article-title":"Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-\u03b2 and miR23a transfer","volume":"5","author":"Berchem","year":"2015","journal-title":"Oncoimmunology"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-11-1977","article-title":"Tumor suppressive microRNAs miR-34a\/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D","volume":"72","author":"Heinemann","year":"2012","journal-title":"Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-11-2671","article-title":"MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells","volume":"72","author":"Tsukerman","year":"2012","journal-title":"Cancer Res"},{"key":"B144","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s13046-018-0965-2","article-title":"Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts","volume":"37","author":"Zhou","year":"2018","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2019.4933","article-title":"Bladder cancer cell-secreted exosomal miR-21 activates the PI3K\/AKT pathway in macrophages to promote cancer progression","volume":"56","author":"Lin","year":"2019","journal-title":"Int J Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4638","article-title":"Serum exosomal miR\u201016\u20105p functions as a tumor inhibitor and a new biomarker for PD\u2010L1 inhibitor\u2010dependent immunotherapy in lung adenocarcinoma by regulating PD\u2010L1 expression","volume":"11","author":"Chen","year":"2022","journal-title":"Cancer Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.811364","article-title":"Co-expression of miR155 or LSD1 shRNA increases the anti-tumor functions of CD19 CAR-T cells","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-018-0600-x","article-title":"miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy","volume":"11","author":"Huang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132334","article-title":"MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors","volume":"5","author":"Marschner","year":"2020","journal-title":"JCI Insight"},{"key":"B150","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1182\/blood-2018-99-119861","article-title":"Phase 1 trial of cobomarsen, an inhibitor of Mir-155, in cutaneous T cell lymphoma","volume":"132","author":"Querfeld","year":"2018","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093387","article-title":"The interplay between microRNAs and the components of the tumor microenvironment in B-cell Malignancies","volume":"21","author":"El-Daly","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030550","article-title":"Extracellular miRNAs as predictive biomarkers for glypican-3-derived peptide vaccine therapy response in ovarian clear cell carcinoma","volume":"13","author":"Ukai","year":"2021","journal-title":"Cancers"},{"key":"B153","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3892\/or.2016.5267","article-title":"MicroRNA-6826 and -6875 in plasma are valuable non-invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer","volume":"37","author":"Kijima","year":"2016","journal-title":"Oncol Rep"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1724761","article-title":"Overexpression of microRNA-155 enhances the efficacy of dendritic cell vaccine against breast cancer","volume":"9","author":"Hodge","year":"2020","journal-title":"OncoImmunology"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2009.188","article-title":"E2F1-inducible microRNA 449a\/b suppresses cell proliferation and promotes apoptosis","volume":"17","author":"Liz\u00e9","year":"2010","journal-title":"Cell Death Differ"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031380","article-title":"miRNAs and biomarkers in testicular germ cell tumors: An update","volume":"22","author":"Martino","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2022.2031408","article-title":"microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3","volume":"13","author":"Li","year":"2022","journal-title":"Bioengineered"},{"key":"B158","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1158\/1538-7445.am2015-2875","article-title":"Abstract 2875: p53 regulation of PDL1 is mediated through miR-34a","volume":"75","author":"Cortez","year":"2015","journal-title":"Cancer Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2007.05.010","article-title":"Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis","volume":"26","author":"Chang","year":"2007","journal-title":"Mol Cell"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv303","article-title":"PDL1 regulation by p53 via miR-34","volume":"108","author":"Cortez","year":"2015","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020089","article-title":"miRNA-based therapeutics in the era of immune-checkpoint inhibitors","volume":"14","author":"Huemer","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3390\/genes12081206","article-title":"A systematic review on the therapeutic potentiality of PD-L1-inhibiting microRNAs for triple-negative breast cancer: Toward single-cell sequencing-guided biomimetic delivery","volume":"12","author":"Shadbad","year":"2021","journal-title":"Genes"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15155","article-title":"p53\/microRNA-34 axis in cancer and beyond","volume":"9","author":"Pan","year":"2023","journal-title":"Heliyon"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s323898","article-title":"Rapid response to pembrolizumab in a chemo-refractory testicular germ cell cancer with microsatellite instability-high","volume":"14","author":"Kawai","year":"2021","journal-title":"OncoTargets Ther"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1074477","article-title":"Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1186\/s12964-024-01912-3","article-title":"Refractory testicular germ cell tumors are highly sensitive to the targeting of polycomb pathway demethylases KDM6A and KDM6B","volume":"22","author":"Shokry","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13811","article-title":"Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine","volume":"8","author":"Albany","year":"2016","journal-title":"Oncotarget"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr586","article-title":"Nucleoside modifications in RNA limit activation of 2\u2032-5\u2032-oligoadenylate synthetase and increase resistance to cleavage by RNase L","volume":"39","author":"Anderson","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02801-8","article-title":"A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy","volume":"42","author":"Abdelaal","year":"2023","journal-title":"Oncogene"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2017.3164","article-title":"Expression, regulation and mechanism of action of the miR-17\u201392 cluster in tumor cells (Review)","volume":"40","author":"Fang","year":"2017","journal-title":"Int J Mol Med"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2013.125","article-title":"The miR-17\/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease","volume":"20","author":"Mogilyansky","year":"2013","journal-title":"Cell Death Differ"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402090","article-title":"Translational repression of E2F1 mRNA in carcinoma in situ and normal testis correlates with expression of the miR-17\u201392 cluster","volume":"14","author":"Novotny","year":"2007","journal-title":"Cell Death Differ"},{"key":"B174","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41420-022-00919-4","article-title":"Tumor stem cell-derived exosomal microRNA-17-5p inhibits anti-tumor immunity in colorectal cancer via targeting SPOP and overexpressing PD-L1","volume":"8","author":"Sun","year":"2022","journal-title":"Cell Death Discov"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002236","article-title":"Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM","volume":"3","author":"Fontana","year":"2008","journal-title":"PloS One"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf214","article-title":"RNA therapeutics in kidney diseases: prospects and current status","volume":"18","author":"Schena","year":"2025","journal-title":"Clin Kidney J"},{"key":"B177","unstructured":"A study of RGLS4326 in patients with autosomal dominant polycystic kidney disease\n          \n          \n          \n          2021"},{"key":"B178","doi-asserted-by":"publisher","first-page":"10.1681\/ASN.2024w1ps7ssb","DOI":"10.1681\/asn.2024w1ps7ssb","article-title":"RGLS8429 increases urinary PC1 and PC2 and may reduce height-adjusted total kidney volume (htTKV) in patients with ADPKD","volume":"35","author":"Yu","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"10762","DOI":"10.1038\/s41467-025-65799-5","article-title":"The nucleobase guanine at the 3\u2019-terminus of oligonucleotide RGLS4326 drives off-target AMPAR inhibition and CNS toxicity","volume":"16","author":"Valencia","year":"2025","journal-title":"Nat Commun"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2013.13","article-title":"Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer","volume":"15","author":"Koster","year":"2013","journal-title":"Expert Rev Mol Med"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1172\/jci41939","article-title":"Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer","volume":"120","author":"Koster","year":"2010","journal-title":"J Clin Investig"},{"key":"B182","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-0280","article-title":"SD-101 in combination with pembrolizumab in advanced melanoma: Results of a phase Ib, multicenter study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discov"},{"key":"B185","article-title":"The expression of Toll-Like Receptors (TLRs) in testicular cancer: A case control study","volume":"11","author":"Shapouri","year":"2013","journal-title":"Iran J Reprod Med"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-2235","article-title":"Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced\/metastatic solid tumors or lymphomas: An open-label, multicenter, phase Ib study","volume":"29","author":"Meric-Bernstam","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B187","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/s41467-025-57257-z","article-title":"PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer","volume":"16","author":"Ran","year":"2025","journal-title":"Nat Commun"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1480417","article-title":"PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for","volume":"15","author":"Parola","year":"2024","journal-title":"Front Genet"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032495","article-title":"Integrated microarray-based data analysis of miRNA expression profiles: Identification of novel biomarkers of cisplatin-resistance in testicular germ cell tumors","volume":"24","author":"Ro\u0161ka","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.08.132","article-title":"miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1\/GRB2","volume":"107","author":"Xu","year":"2018","journal-title":"BioMed Pharmacother"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.867886","article-title":"Mir-378a-3p acts as a tumor suppressor in colorectal cancer stem-like cells and affects the expression of MALAT1 and NEAT1 lncRNAs","volume":"12","author":"Castellani","year":"2022","journal-title":"Front Oncol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3583","article-title":"A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer","volume":"10","author":"Albany","year":"2020","journal-title":"Cancer Med"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.reth.2025.01.019","article-title":"Exosome-based miRNA delivery: Transforming cancer treatment with mesenchymal stem cells","volume":"28","author":"Balaraman","year":"2025","journal-title":"Regener Ther"},{"key":"B194","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s12964-024-01906-1","article-title":"Exosome-based immunotherapy as an innovative therapeutic approach in melanoma","volume":"22","author":"Babaei","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70095","article-title":"Exosomes: a double\u2010edged sword in cancer immunotherapy","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1080\/17435889.2025.2492542","article-title":"Microrna-targeted nanoparticle delivery systems for cancer therapy: current status and future prospects","volume":"20","author":"Lou","year":"2025","journal-title":"Nanomedicine"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.11.9.15185","article-title":"Chitosan hydrogel for localized gene silencing","volume":"11","author":"Han","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1038\/nmat4497","article-title":"Self-assembled RNA-triple-helix hydrogel scaffold for microrna modulation in the tumor microenvironment","volume":"15","author":"Conde","year":"2016","journal-title":"Nat Mater"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-023-01472-w","article-title":"Hydrogels for RNA delivery","volume":"22","author":"Zhong","year":"2023","journal-title":"Nat Mater"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.3390\/gels11080633","article-title":"Advances in hydrogel-based delivery of RNA drugs for antitumor therapy","volume":"11","author":"Xu","year":"2025","journal-title":"Gels"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433050","article-title":"Application of hydrogels in cancer immunotherapy: a bibliometric analysis","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01276-w","article-title":"A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors","volume":"40","author":"Adra","year":"2022","journal-title":"Investig N Drugs"},{"key":"B203","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10020-023-00636-3","article-title":"Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options","volume":"29","author":"Skowron","year":"2023","journal-title":"Mol Med"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1002\/path.2230","article-title":"High\u2010throughput microRNAome analysis in human germ cell tumors","volume":"213","author":"Gillis","year":"2007","journal-title":"J Pathol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-17-3841","article-title":"Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN\/PI3K\u03b3 to promote pancreatic cancer metastasis","volume":"78","author":"Wang","year":"2017","journal-title":"Cancer Res"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.07.011","article-title":"Hypoxic glioma cell-secreted exosomal miR-301a activates Wnt\/\u03b2-catenin signaling and promotes radiation resistance by targeting TCEAL7","volume":"27","author":"Yue","year":"2019","journal-title":"Mol Ther"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3379","article-title":"Microrna-301a promotes cell proliferation via PTEN targeting in Ewing\u2019s sarcoma cells","volume":"48","author":"Kawano","year":"2016","journal-title":"Int J Oncol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114512","article-title":"Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K\/PTEN and MEK\/ERK pathways","volume":"161","author":"Granda-D\u00edaz","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34697","article-title":"Testicular germ cell tumor cells release microRNA\u2010containing extracellular vesicles that induce phenotypic and genotypic changes in cells of the tumor microenvironment","volume":"154","author":"Alonso\u2010Crisostomo","year":"2024","journal-title":"Int J Cancer"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092619","article-title":"The subtype identity of testicular cancer cells determines their immunostimulatory activity in a coculture model","volume":"15","author":"Gayer","year":"2023","journal-title":"Cancers"},{"key":"B211","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s41419-018-1021-z","article-title":"A miR-125b\/CSF1-CX3CL1\/tumor-associated macrophage recruitment axis controls testicular germ cell tumor growth","volume":"9","author":"Batool","year":"2018","journal-title":"Cell Death Dis"},{"key":"B212","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12935-022-02570-6","article-title":"Exosomal miR-301a-3p from esophageal squamous cell carcinoma cells promotes angiogenesis by inducing M2 polarization of macrophages via the PTEN\/PI3K\/AKT signaling pathway","volume":"22","author":"Shou","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"Henau","year":"2016","journal-title":"Nature"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-3313","article-title":"Eganelisib, a first-in-class PI3K\u03b3 inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009160","article-title":"Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment","volume":"12","author":"O\u2019Connell","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-15-0283","article-title":"Loss of PTEN promotes resistance to T cell\u2013mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0834-6","article-title":"Emerging role of PTEN loss in evasion of the immune response to tumors","volume":"122","author":"Vidotto","year":"2020","journal-title":"Br J Cancer"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002279","article-title":"Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal","volume":"9","author":"Isoyama","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B220","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/celldisc.2015.5","article-title":"Modulation of tumorigenesis by the pro-inflammatory microRNA miR-301a in mouse models of lung cancer and colorectal cancer","volume":"1","author":"Ma","year":"2015","journal-title":"Cell Discov"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11757","article-title":"Serum level of microRNA-375-3p is not a reliable biomarker of teratoma","volume":"34","author":"Belge","year":"2020","journal-title":"Vivo"},{"key":"B222","doi-asserted-by":"publisher","first-page":"1647655","DOI":"10.21037\/tau-20-1349","article-title":"The combination of microRNA-371a-3p and 375-5p can distinguish viable germ cell tumor and teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens","volume":"10","author":"Kremer","year":"2021","journal-title":"Transl Androl Urol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042156","article-title":"MicroRNAs in testicular germ cell tumors: the teratoma challenge","volume":"25","author":"Yodkhunnatham","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1847225\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:48:08Z","timestamp":1781156888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1847225\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":223,"alternative-id":["10.3389\/fimmu.2026.1847225"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1847225","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"article-number":"1847225"}}